Esperion Announces Submission of Application for Expanded Indication with the European Medicines Agency (EMA) for NILEMDO® (bempedoic acid) Tablet and NUSTENDI® (bempedoic acid and ezetimibe) Tablet
Source: Nasdaq GlobeNewswire / 28 Jun 2023 07:00:01 America/Chicago